LeMaitre Vascular (NASDAQ:LMAT) Issues FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.840-2.940 for the period, compared to the consensus EPS estimate of 3.000. The company issued revenue guidance of $274.3 million-$278.3 million, compared to the consensus revenue estimate of $279.9 million. LeMaitre Vascular also updated its Q3 2026 guidance to 0.660-0.710 EPS.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $25.49 on Wednesday, hitting $80.29. The company had a trading volume of 961,375 shares, compared to its average volume of 259,626. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of 29.78, a P/E/G ratio of 2.88 and a beta of 0.53. The stock has a 50 day moving average price of $97.41 and a 200 day moving average price of $100.04. LeMaitre Vascular has a 1-year low of $79.39 and a 1-year high of $118.01. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. During the same quarter in the prior year, the business posted $0.60 EPS. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Analysts expect that LeMaitre Vascular will post 3 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be paid a dividend of $0.25 per share. The ex-dividend date is Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LMAT shares. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Wells Fargo & Company decreased their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a report on Wednesday. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $110.60.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider owned 3,749 shares in the company, valued at $401,143. The trade was a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 54,453 shares of company stock worth $5,906,174 in the last 90 days. Company insiders own 7.40% of the company’s stock.

Key LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, while earnings per share rose to $0.74 from $0.60 a year earlier. The company also maintained strong profitability, with a 24.35% net margin. LeMaitre Q2 2026 Financial Results
• Positive Sentiment: LeMaitre declared a quarterly dividend of $0.25 per share, payable September 3 to shareholders of record August 20. The dividend represents an annualized yield of approximately 1.1%.
• Neutral Sentiment: Wells Fargo lowered its price target from $104 to $94 and maintained an “equal weight” rating, implying potential upside from the recent trading level but signaling a more cautious valuation view. Benzinga
• Negative Sentiment: Q2 EPS of $0.74 missed the $0.81 consensus estimate, while revenue of $70.38 million fell short of the $71.47 million forecast. LeMaitre Q2 Earnings and Revenues Lag Estimates
• Negative Sentiment: Management’s updated third-quarter guidance is below consensus: EPS of $0.66–$0.71 versus $0.73 expected and revenue of $66.3–$68.3 million versus $69.0 million expected.
• Negative Sentiment: Full-year 2026 guidance was also reduced to EPS of $2.84–$2.94 and revenue of $274.3–$278.3 million, below consensus estimates of $3.00 and $279.9 million, respectively.
• Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” adding to the cautious investor reaction. Finviz

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. raised its holdings in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular in the second quarter valued at about $47,000. Quarry LP grew its position in LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after acquiring an additional 529 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in LeMaitre Vascular during the fourth quarter worth about $68,000. Finally, Kemnay Advisory Services Inc. acquired a new position in LeMaitre Vascular during the fourth quarter worth about $80,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.